Antioxidants / anti-aging

2CARE Study Ends Early

The Huntington Study Group has ended its Phase III trial of CoQ10 early because of futility.  The study has been going on for a number of years now and early analysis of the data indicates that it is very unlikely to prove to be effective.

It’s time to discontinue CoQ10 as a supplement.   Mouse studies discussed here at the Lighthouse have had inconsistent results which is why we were not hopeful that this supplement would work.

Grape Derived Polyphenols

Researchers at the Mount Sinai School of Medicine in New York have investigated grape derived polyphenol extract (GDPE) as a potential treatment for Huntington's disease. They found promising results in a cell model, a drosophila model, and the R6/2 mice.

In previous studies, the authors investigated the bioavailability of GDPE and found that although it is metabolized in the gut, it does cross the blood brain barrier and can be detected in the brain.

Syndicate content